Skip to main content
On Our Radar

Response to the S4 Study Results in Neurology

By September 9, 2020March 2nd, 2023No Comments

Response to the S4 Study Results in Neurology

A group of international experts responded to the publication of the recent Systemic Synuclein Sampling Study (S4), which found alpha-synuclein to be a specific—but not sensitive—marker of Parkinson’s disease. Their letter details how the study’s methods, rather than the specificity of alpha-synuclein as a marker for Parkinson’s disease, may have produced the results.

CND Life Sciences

CND Life Sciences is the creator of the Syn-One Test™, the world’s first commercially available test to visualize abnormal, phosphorylated alpha-synuclein in cutaneous nerve fibers. The test is an objective, evidence-based diagnostic tool to aid in the diagnosis of Parkinson’s disease, dementia with Lewy bodies, multiple system atrophy, pure autonomic failure, or REM sleep behavior disorder.